Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 4
---
 Liabilities” for additional information.

For investors outside of the United States: Neither we nor the Selling Shareholder have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.

In this prospectus, “we,” “us,” “our,” the “Company” and “NLS” refer to NLS Pharmaceutics Ltd., and its wholly owned subsidiary, NLS Pharmaceutics Inc., a Delaware corporation.

Our reporting currency and functional currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to “dollars,” “USD” or “$” mean U.S. dollars, and references to “CHF” are to the Swiss Franc. U.S. dollar translations of CHF amounts presented in this prospectus were done on different dates in accordance with the date as of such entry in the Company’s books and are derived from our audited financial statements incorporated by reference in this prospectus. U.S. dollar translations of CHF amounts presented in this prospectus that are not derived from our audited financial statements incorporated by reference in this prospectus are translated using the rate of CHF 1.00 to $1.1034, based on the exchange rate provided by the Swiss Federal Tax Administration on December 31, 2024.

All information included herein relating to shares or price per share reflects the 1-for-40 reverse split effected by us on September 27, 2024. Further, on January 14, 2025, the shareholders of the Company approved a change in the par value of our Common Shares from CHF 0.80 to CHF 0.03 per share, effective January 17, 2025.

<div align='center'>ii

ABOUT THIS PROSPECTUS</div>

This prospectus describes the general manner in which the Selling Shareholder identified in this prospectus may offer from time to time up to 645,161 of our Common Shares, consisting of: (i) 161,290 Common Shares issued in a private placement pursuant to the December SPA, (ii) 75,000 Common Shares issued pursuant to the October Debt SPA, and (iii) 408,871 Common Shares issuable upon the conversion of certain of the Company’s PPCs pursuant to the October